Vancouver, British Columbia--(Newsfile Corp. - March 19, 2014) - New York based investment firm Taglich Brothers has initiated coverage on CollabRx Inc. (NASDAQ: CLRX). Analyst Juan Noble gives the company a speculative buy rating, and a 12 month price target of $10.00, a premium of 188% to the $3.47 price on February 25th, the day the report was issued.

InvestmentPitch.com has produced a "video research alert" about CollabRx based on this report. If this link is not enabled, please visit www.InvestmentPitch.com and enter "CollabRx" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_twi380zx/Taglich-Brothers-Initiated-Coverage-on-CollabRx-Inc-NASDAQ-CLRX

Unlike genomic laboratories that bundle in-house analytics with their test results, San Francisco-based CollabRx is a pure bioinformatics company. The company's specialized medical database is continually updated by software systems, tapping into an array of online medical and scientific resources.

By leveraging its network of more than 75 uncompensated medical advisors, organized by cancer specialty, from leading academic institutions, the company is able to provide substantial value-added content to results of genetic tests ordered for the diagnosis and evaluation of cancer cases. Physicians utilize the views of these advisors, together with the continually updated online sources, to prioritize treatment strategies.

Sharp reductions in the cost of genetic testing have placed the service within easier reach of physicians, contributing to an increase in demand. UnitedHealth projects the market for molecular diagnostic and genetic tests will increase to $15 billion to $25 billion by 2021. As cancer is caused by genetic mutations, the increase in the number of genomic tests should improve diagnosis and the development of targeted therapies.

The company recently launched two products. Sales of the Genetic Variation Annotation™ service for laboratories and Therapy Finders™ for physicians are expected to accelerate during the next year. By utilizing these services, reference and hospital laboratories have access to a high-value service without the need to make sizeable investments in computer equipment and software development.

Analyst Juan Noble stated, "CollabRx should start to show substantive revenue in FY2015 and potentially see its revenue surge in FY2017 as the company's GVA service is more heavily used by an increasing number of laboratories. CollabRx could, in our view, achieve a revenue ramp to $16.5 million by 2020."

With the American Cancer Society projecting that cancer will kill an estimated 600,000 in 2014, the company is initially concentrating on cancer, but could expand into other areas in the future.

The company currently trades at $3.25, well below the $10.00 target price, and with 2 million shares outstanding, the company is capitalized at $6.5 million.

For more information please visit the company's website www.collabrx.com or contact Thomas Mika, President & CEO at 415-248-5350 or email tmika@collabrx.com.

Investor relations is handled by Jeff Ramson of ProActive Capital Resources, who can be reached at 646-863-6893 or by email at jramson@proactivecrg.com.

For more information about Taglich Brothers or to obtain a copy of their extensive research report, please visit the company's website www.taglichbrothers.com or call Richard Oh at 631-757-1500.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing corporate interviews and three minute videos based on news releases and research reports. Please visit InvestmentPitch.com and browse our extensive library of investment videos.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan@investmentpitch.com